Taysha Gene Therapies is a clinical-stage biotechnology company singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), in both rare and large patient populations.
| Ownership Public Company |
| Funding $125M |
Taysha Gene Therapies is a clinical-stage biotechnology company focused on discovering, developing, and commercializing adeno-associated virus (AAV)-based gene therapies for monogenic diseases of the
Biotechnology company focused on the discovery, development, and commercialization of gene therapies for CNS disorders.
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with Taysha Gene Therapies